Contrast-enhanced magnetic resonance imaging of tumours of the central nervous system: a clinical review.
The clinical application of the intravascular paramagnetic contrast agent gadolinium-DTPA for magnetic resonance imaging (MRI) imaging of tumours of the central nervous system (CNS) has been assessed over the past 3 years. Various patterns of contrast enhancement were observed, and situations in MRI where the administration of contrast medium may be useful have been defined. These include lesions which are isointense with normal brain matter, the separation of tumour from surrounding oedema, evaluation of the degree of blood-brain barrier breakdown, delineation of tumours obscured by overlying calcification on computed tomography (CT) and in the investigation of lesions in anatomical areas where CT has known limitations (brain stem, cervical spine). Changes in relaxation times in normal and abnormal tissues following contrast medium, toxicity and dosage of gadolinium-DTPA, and MRI pulse sequence techniques are reviewed.
D001254:Astrocytoma / Q000175:diagnosis; D001932:Brain Neoplasms / Q000175:diagnosis*; D001943:Breast Neoplasms / Q000175:diagnosis; D005260:Female; D005682:Gadolinium; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008545:Melanoma / Q000175:diagnosis; D008579:Meningioma / Q000175:diagnosis*; D009463:Neuroma / Q000175:diagnosis*; D009464:Neuroma, Acoustic / Q000175:diagnosis*; D010051:Ovarian Neoplasms / Q000175:diagnosis; D004369:Pentetic Acid; D013120:Spinal Cord Neoplasms / Q000175:diagnosis*
D004369:Pentetic Acid; D005682:Gadolinium